

Amendments to the Claims:

1. (Currently Amended) A polymorphic form of 9-nitrocamptothecin, the polymorph being in crystal form C wherein the crystal form C is characterizable as having, by differential scanning calorimetry, no observable endotherm and an exotherm at between 273.6 and 275.6 °C, and a solution NMR spectrum with multiplets at 1.7 and 3.7 ppm shifts, and an X-ray powder diffraction pattern with diffraction lines at $^{\circ}2\theta$ values 6.7, 12.5, 14.0 and 23.9 for Cu K α radiation of wavelength 1.5406 Angstrom.
2. (Currently Amended) A polymorphic form of The 9-nitrocamptothecin crystal form according to claim 1, the polymorph being wherein the crystal form is further characterizable as having an exotherm by differential scanning calorimetry at between 274.1 and 275.1 °C.
3. (Currently Amended) A polymorphic form of The 9-nitrocamptothecin crystal form according to claim 1, the polymorph being wherein the crystal form is further characterizable as having an exotherm by differential scanning calorimetry at between 274.4 and 274.8 °C.
4. (Currently Amended) A polymorphic form of The 9-nitrocamptothecin crystal form according to claim 1, the polymorph being wherein the crystal form is further characterizable as having an exotherm by differential scanning calorimetry at between 274.5 and 274.7 °C.

5-8. (Canceled)

9. (Currently Amended) A polymorphic form of The 9-nitrocamptothecin crystal form according to claim 1, wherein the crystal form is crystallized from tetrahydrofuran.

10-13. (Canceled)

14. (Currently Amended) A pharmaceutical composition comprising:
a pharmaceutical carrier; and

a polymorphic form of 9-nitrocamptothecin in crystal form C, the polymorph being wherein the crystal form is characterizable as having, by differential scanning calorimetry, no observable endotherm and an exotherm at between 273.6 and 275.6 °C, and a solution NMR spectrum with multiplets at 1.7 and 3.7 ppm shifts, and an X-ray powder diffraction pattern with diffraction lines at °2θ values 6.7, 12.5, 14.0 and 23.9 for Cu Kα radiation of wavelength 1.5406 Angstrom.

15. (Currently Amended) A The pharmaceutical composition according to claim 14, the polymorph being wherein the crystal form is further characterizable as having an exotherm by differential scanning calorimetry at between 274.1 and 275.1 °C.

16. (Currently Amended) A The pharmaceutical composition according to claim 14, the polymorph being wherein the crystal form is further characterizable as having an exotherm by differential scanning calorimetry at between 274.4 and 274.8 °C.

17. (Currently Amended) A The pharmaceutical composition according to claim 14, the polymorph being wherein the crystal form is further characterizable as having an exotherm by differential scanning calorimetry at between 274.5 and 274.7 °C.

18-25. (Canceled)

26. (Currently Amended) A method of preparing a polymorphic form of 9-nitrocamptothecin in crystal form C as in claim 1, the method comprising:
crystallizing 9-nitrocamptothecin from tetrahydrofuran.

27. (Currently Amended) A The method according to claim 26, the polymorph being wherein the crystal form is characterizable as having, by differential scanning calorimetry, no observable endotherm and an exotherm at between 273.6 and 275.6 °C, and a solution NMR spectrum with multiplets at 1.7 and 3.7 ppm shifts, and an X-ray powder diffraction pattern with diffraction lines at °2θ values 6.7, 12.5, 14.0 and 23.9 for Cu Kα radiation of wavelength 1.5406 Angstrom.

Appl. No. 10/080,530
Amend. Dated April 18, 2005
Non-Final Office Action dated Jan. 19, 2005

28-30. (Canceled)